02511 HIGHTIDE-B
- 1.410
- -0.070-4.73%
HIGHTIDE-B News
HIGHTIDE-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
HIGHTIDE-B: NOTICE OF DATE OF BOARD MEETING
HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
HIGHTIDE-B: VOLUNTARY ANNOUNCEMENTBUSINESS UPDATE
HIGHTIDE-B: HIGHTIDE COMPLETES PATIENT ENROLLMENT OFPHASE III CLINICAL TRIALS OF HTD1801 FORTHE TREATMENT OF TYPE 2 DIABETES MELLITUS
HIGHTIDE-B: VOLUNTARY ANNOUNCEMENTUNUSUAL PRICE MOVEMENTS
HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
HIGHTIDE-B: POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 16, 2024
HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
HIGHTIDE-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
HIGHTIDE-B: 2023 ANNUAL REPORT
HIGHTIDE-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETINGTO BE HELD ON THURSDAY, MAY 16, 2024
HIGHTIDE-B: NOTICE OF ANNUAL GENERAL MEETING
HIGHTIDE-B: (1) PROPOSED GRANTING OF GENERAL MANDATESTO ISSUE SHARES, RESELL TREASURY SHARES ANDREPURCHASE SHARES;(2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;(3) PROPOSED RE-APPOINTMENT OF AUDITOR;AND(4) NOTICE OF ANNUAL GENERAL MEETING
HIGHTIDE-B: COMPLETION OF PATIENT ENROLLMENT IN PHASE IIb CLINICAL TRIAL EVALUATING HTD1801 IN MASH
HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
HIGHTIDE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
HIGHTIDE-B: NOTICE OF DATE OF BOARD MEETING
HIGHTIDE-B: Notification Letter and Reply Form to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Analysis
Price Target
No Data
